<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445793</url>
  </required_header>
  <id_info>
    <org_study_id>HS-3145</org_study_id>
    <nct_id>NCT03445793</nct_id>
  </id_info>
  <brief_title>: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)</brief_title>
  <official_title>: TRANSITION: An Observational Study of the Effects on Sweat Chloride and Clinical Outcomes of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center study of clinical and laboratory outcomes in patients â‰¥ 12 who&#xD;
      transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be&#xD;
      measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. Change&#xD;
      from baseline at 6 months pre-specified will be reported. The length of study participation&#xD;
      will be approximately 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While cystic fibrosis (CF) therapeutic development previously targeted the signs and symptoms&#xD;
      of the disease, in the last 5 years, two drugs that treat the basic defect in CF have been&#xD;
      approved, ivacaftor (iva) and lumacaftor/ivacaftor (lum/iva). This class of drugs, deemed&#xD;
      cystic fibrosis transmembrance conductance regulator (CFTR) modulators, variably improve CFTR&#xD;
      function as measured by pilocarpine iontophoresis and sweat collection, and clinical outcomes&#xD;
      including lung function, body mass index (BMI), rate of exacerbations and patient reported&#xD;
      quality of life.&#xD;
&#xD;
      In patients with the G551D mutation who received iva, there was a marked decrease in sweat&#xD;
      chloride and marked improvement in lung function as measured by absolute change from baseline&#xD;
      of percent predicted expiratory volume in 1 second (ppFEV1). The clinical outcomes assessed&#xD;
      in the phase III studies of lum/iva and tez/iva were similar, and included lung function,&#xD;
      rate of pulmonary exacerbations, BMI, and CFQ-R scores. While the correlation between&#xD;
      improvement in sweat chloride and lung function is poor, and a minimum threshold for change&#xD;
      in sweat chloride that correlates with clinical outcomes has yet to be defined, it has also&#xD;
      not been determined if an increase in sweat chloride caused by a transition from one drug to&#xD;
      another would adversely impact clinical outcomes. Outcomes between the phase III studies of&#xD;
      lum/iva and tez/iva were similar, tez/iva has three advantages that are likely to make it&#xD;
      more appealing to patients and providers than lum/iva including positive clinical efficacy&#xD;
      data, fewer drug-drug interactions, and an improved tolerance profile.&#xD;
&#xD;
      Following tez/iva approval, a rapid uptake of tez/iva for patients homozygous for F508del&#xD;
      CFTR is expected; as a result of the transition from lum/iva to tez/iva, sweat chloride will&#xD;
      increase possibly resulting in an adverse impact on clinical outcomes. This study aims to&#xD;
      determine the rationale for patient transition from lum/iva to tez/iva, in addition to&#xD;
      evaluate the impact of transition on CFTR function, pulmonary health, gastrointestinal&#xD;
      health, and general health. While it is possible that there will be no change in sweat&#xD;
      chloride or small changes that are without clinical significance, systematic collection of&#xD;
      data as patients transition from lum/iva to tez/iva would permit rapid identification of any&#xD;
      safety issues. Because the U.S. always leads the way with approval and reimbursement of new&#xD;
      therapeutics, our experience with this transition will help guide its conduct for physicians&#xD;
      and patients in the rest of the world.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sweat Chloride Concentration in Millimoles/Liter From Baseline at 6 Months Pre-specified to be Reported</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Sweat chloride is a measure of CFTR function. The calculations represent the average change from baseline to the average change at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rationale for Transition Per Physician Questionnaire</measure>
    <time_frame>1 day (the questionnaire is done once at visit 1)</time_frame>
    <description>Questionnaire to determine the treating physician's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rationale for Transition Per Subject Questionnaire</measure>
    <time_frame>1 day (the questionnaire is done once at visit 1)</time_frame>
    <description>Questionnaire to determine the subject's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbations</measure>
    <time_frame>One year prior to study entry (time of consent) and during study participation</time_frame>
    <description>Number of pulmonary exacerbations requiring oral or IV antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted (ppFEV1) Value From Baseline at 6 Months Pre-specified to be Reported</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Pulmonary function by spirometry, percent predicted forced expiratory volume in 1 second. The calculations represent the average change from baseline to the average change at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline at 6 Months</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>CF-related quality of life measure is a validated, CF specific, patient reported outcome (PRO). This portion of the PRO is specific to respiratory symptoms. The scaled score for each domain ranges from 0 (worst condition) to 100 (best condition), with higher scores indicating better health in respiratory domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight in Kilograms From Baseline at 6 Months Pre-specified to be Reported</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Weight is a reflection of nutrition status in CF and is expected to improve with CFTR modulation. The calculations represent the average change from baseline to the average change at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI in kg/m^2 From Baseline at 6 Months Pre-specified to be Reported</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>BMI is a reflection of nutrition status in CF and is expected to improve with CFTR modulation. The calculations represent the average change from baseline to the average change at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of People With Undetectable or Normal Fecal Elastase Measurements at 6 Months Pre-specified to be Reported</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal elastase in micrograms/gram. Fecal elastase is a measure of pancreatic function: Less than 100 mcg/g indicates severe exocrine pancreatic insufficiency, 100-200 mcg/g indicates moderate to mild insufficiency, greater than 200 indicates normal pancreatic function. The count represents the number of participants with either an undetectable fecal elastase level or normal level at 6 months, indicating change in pancreatic function at 6 months.</description>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Cystic Fibrosis (CF)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic fibrosis with 2 copies of F508del mutation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of CF&#xD;
&#xD;
          -  Male or female subjects greater than or equal to 12 years of age&#xD;
&#xD;
          -  Ability to reproducibly perform spirometry testing&#xD;
&#xD;
          -  Physician decision to treat with tezacaftor/ivacaftor (Smydeko)&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent or assent and comply with&#xD;
             the requirements of the study&#xD;
&#xD;
          -  Continuous use of orkambi for at least 1 month prior to visit 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to tezacaftor and/or ivacaftor&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data&#xD;
&#xD;
          -  Any acute lower respiratory symptoms treated with oral, inhaled or intravenous&#xD;
             antibiotics (IV) or systemic corticosteroids within the 2 weeks prior to Visit 1&#xD;
&#xD;
          -  Major or traumatic surgery within 12 weeks prior to Visit 1&#xD;
&#xD;
          -  For women of child-bearing potential: a positive pregnancy test at Visit 1&#xD;
&#xD;
          -  Unable or unwilling to fast (including no enteric tube feedings) for at least 6 hours&#xD;
             prior each visit&#xD;
&#xD;
          -  Initiation of any new chronic therapy within 4 weeks prior to Visit 1&#xD;
&#xD;
          -  Use of an investigational agent within 28 days prior to Visit 1&#xD;
&#xD;
          -  Use of chronic oral corticosteroids within 28 days prior to Visit 1&#xD;
&#xD;
          -  Treatment for nontuberculous mycobacterial (NTM) infection, consisting of greater than&#xD;
             or equal to two antibiotics (oral, IV, and/or inhaled) within 28 days prior to Visit 1&#xD;
&#xD;
          -  History of lung or liver transplantation, or listing for organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Taylor-Cousar, MD, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Heatlh</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2021</results_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jennifer Taylor-Cousar</investigator_full_name>
    <investigator_title>MD, Principal Investigator, Co-Director/CF TDN Director, Adult CF Program</investigator_title>
  </responsible_party>
  <keyword>DeltaF508deletion (F508del) mutation in 2 copies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03445793/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03445793/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Single center recruitment from March 2018 until November 2019.</recruitment_details>
      <pre_assignment_details>Participant must complete baseline visit while on lumacaftor/ivacaftor prior to transition to tezacaftor/ivacaftor.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Observational</title>
          <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observational</title>
          <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at time of consent</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cystic Fibrosis Mutation Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Homozygous for F508del</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Heterozygous for F508del</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Sweat Chloride Concentration in Millimoles/Liter From Baseline at 6 Months Pre-specified to be Reported</title>
        <description>Sweat chloride is a measure of CFTR function. The calculations represent the average change from baseline to the average change at 6 months.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride Concentration in Millimoles/Liter From Baseline at 6 Months Pre-specified to be Reported</title>
          <description>Sweat chloride is a measure of CFTR function. The calculations represent the average change from baseline to the average change at 6 months.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="-12.1" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rationale for Transition Per Physician Questionnaire</title>
        <description>Questionnaire to determine the treating physician's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
        <time_frame>1 day (the questionnaire is done once at visit 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Rationale for Transition Per Physician Questionnaire</title>
          <description>Questionnaire to determine the treating physician's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Side Effects/Intolerance of Orkambi</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No benefit on Orkambi</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rationale for Transition Per Subject Questionnaire</title>
        <description>Questionnaire to determine the subject's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
        <time_frame>1 day (the questionnaire is done once at visit 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Rationale for Transition Per Subject Questionnaire</title>
          <description>Questionnaire to determine the subject's reason for transition to tezacaftor/ivacaftor from lumacaftor/ivacaftor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&quot;Orkambi is no longer working for me&quot;</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No benefit on Orkambi</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Side effects/Intolerance on Orkambi</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Personal desire to try new therapy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Exacerbations</title>
        <description>Number of pulmonary exacerbations requiring oral or IV antibiotics</description>
        <time_frame>One year prior to study entry (time of consent) and during study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Exacerbations</title>
          <description>Number of pulmonary exacerbations requiring oral or IV antibiotics</description>
          <units>Pulmonary Exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Predicted (ppFEV1) Value From Baseline at 6 Months Pre-specified to be Reported</title>
        <description>Pulmonary function by spirometry, percent predicted forced expiratory volume in 1 second. The calculations represent the average change from baseline to the average change at 6 months.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted (ppFEV1) Value From Baseline at 6 Months Pre-specified to be Reported</title>
          <description>Pulmonary function by spirometry, percent predicted forced expiratory volume in 1 second. The calculations represent the average change from baseline to the average change at 6 months.</description>
          <units>percent predicted (ppFEV1)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-5.93" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline at 6 Months</title>
        <description>CF-related quality of life measure is a validated, CF specific, patient reported outcome (PRO). This portion of the PRO is specific to respiratory symptoms. The scaled score for each domain ranges from 0 (worst condition) to 100 (best condition), with higher scores indicating better health in respiratory domain.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline at 6 Months</title>
          <description>CF-related quality of life measure is a validated, CF specific, patient reported outcome (PRO). This portion of the PRO is specific to respiratory symptoms. The scaled score for each domain ranges from 0 (worst condition) to 100 (best condition), with higher scores indicating better health in respiratory domain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" lower_limit="-25.9" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight in Kilograms From Baseline at 6 Months Pre-specified to be Reported</title>
        <description>Weight is a reflection of nutrition status in CF and is expected to improve with CFTR modulation. The calculations represent the average change from baseline to the average change at 6 months.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight in Kilograms From Baseline at 6 Months Pre-specified to be Reported</title>
          <description>Weight is a reflection of nutrition status in CF and is expected to improve with CFTR modulation. The calculations represent the average change from baseline to the average change at 6 months.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI in kg/m^2 From Baseline at 6 Months Pre-specified to be Reported</title>
        <description>BMI is a reflection of nutrition status in CF and is expected to improve with CFTR modulation. The calculations represent the average change from baseline to the average change at 6 months.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI in kg/m^2 From Baseline at 6 Months Pre-specified to be Reported</title>
          <description>BMI is a reflection of nutrition status in CF and is expected to improve with CFTR modulation. The calculations represent the average change from baseline to the average change at 6 months.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" lower_limit="-1.83" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of People With Undetectable or Normal Fecal Elastase Measurements at 6 Months Pre-specified to be Reported</title>
        <description>Fecal elastase in micrograms/gram. Fecal elastase is a measure of pancreatic function: Less than 100 mcg/g indicates severe exocrine pancreatic insufficiency, 100-200 mcg/g indicates moderate to mild insufficiency, greater than 200 indicates normal pancreatic function. The count represents the number of participants with either an undetectable fecal elastase level or normal level at 6 months, indicating change in pancreatic function at 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of People With Undetectable or Normal Fecal Elastase Measurements at 6 Months Pre-specified to be Reported</title>
          <description>Fecal elastase in micrograms/gram. Fecal elastase is a measure of pancreatic function: Less than 100 mcg/g indicates severe exocrine pancreatic insufficiency, 100-200 mcg/g indicates moderate to mild insufficiency, greater than 200 indicates normal pancreatic function. The count represents the number of participants with either an undetectable fecal elastase level or normal level at 6 months, indicating change in pancreatic function at 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Undetectable &lt;15</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal Result</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Observational</title>
          <description>Participants who have cystic fibrosis and are clinically stable at time of transition from Lumacaftor/Ivacaftor to tezacaftor/ivacaftor as a continuous treatment as determined by their clinical physician.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to pulmonary exacerbation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increased cough after stopping Tezacaftor/Ivacaftor</sub_title>
                <description>Subject stopped treatment with Tezacaftor/Ivacaftor after transitioning from Lumacaftor/Ivacaftor</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Exacerbation of Chronic Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation is the small sample size. Less patients with cystic fibrosis transitioned from lumacaftor/ivacaftor to tezacaftor/ivacaftor than expected. The enrolled number of patients left the study underpowered to detect differences.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Taylor-Cousar, Principal Investigator</name_or_title>
      <organization>National Jewish Health</organization>
      <phone>3032702764</phone>
      <email>taylorcousarj@njhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

